← All UbiTiter issuesUbiTiter Issue #20
VHH Repertoires, mRNA Antibody Cocktails, Mucosal Delivery, and ADC Dosing
This issue connects antibody design to the conditions that determine its performance: how sequences are sampled, how chains assemble, where antibodies distribute and how local drug action becomes a clinical prediction.
- VHH repertoires
- OAS-nano
- mRNA-encoded antibodies
- Fc engineering
- polymeric Ig receptor
- mucosal delivery
- antibody-drug conjugates
- quantitative systems pharmacology
The field
This Week in Biologics
Paper 1 · Nucleic Acids Research
OAS-nano: the Observed VHH Space Database
OAS-nano combines 73 million unique VHH sequences with searchable experimental metadata, linking repertoire scale to provenance and sampling context.
Core finding
Gillis et al. assembled 73,063,384 unique VHH sequences from 16 public repertoire datasets and one previously unpublished llama dataset. Under a matched de-duplication procedure, the collection is about five times larger than INDI2. OAS-nano combines those sequences with searchable experimental metadata so the composition of the collection can be examined alongside its diversity.
What's novel
The resource combines scale with information about how the sequences were generated, including primer type, species, isotype, B-cell source and deposition date. This makes experimental provenance part of dataset selection and supports reproducible partitions for sequence-model development.
Limitations
Primer coverage and germline-reference coverage affect which V-gene families can be observed or assigned. Species-matched references support robust somatic-hypermutation analysis only for alpaca among the included species, and user-side error correction influences how rare variation is interpreted.
In context
The collection provides a broad repertoire background, while its metadata provides the background information. For VHH modeling, this connects dataset size to a more substantive question: which biological and experimental distributions the training sequences represent.
Paper 2 · Science Translational Medicine
Orthogonal Fc engineering enables multiplexed delivery of mRNA-encoded bispecific antibodies that constrain viral escape
Orthogonal Fc interfaces reduce chimeric pairing during mRNA coexpression and help preserve the intended identities of a bispecific antibody cocktail.
Core finding
Wec et al. engineered distinct Fc interfaces to favor cognate heavy-chain pairing when several mRNA-encoded antibodies are expressed together. The designs reduced chimeric pairing, and a three-bispecific cocktail produced higher serum neutralization than an otherwise matched wild-type-Fc mixture against KP.3 and an escape variant. The engineered cocktail also neutralized six tested variants in mouse serum and protected mice given the treatment before XBB.1.5 challenge.
What's novel
The Fc designs promote symmetric homodimerization within each antibody, allowing different antibodies to share an expression environment while retaining their intended identities. The study links this assembly strategy to function through a matched cocktail comparison, rather than relying only on the breadth of the final mixture.
Limitations
Total serum neutralization combines the effects of pairing, intrinsic binding affinity and epitope coverage. The substantial activity retained by the wild-type-Fc comparator shows why functional potency alone is an incomplete measure of assembly fidelity; the direct pairing measurements are needed to interpret the engineering effect.
In context
The work connects antibody-cocktail design with the assembly problem introduced by mRNA delivery. Its contribution is the ability to preserve intended molecular combinations during coexpression, making broader antigen coverage compatible with a genetically encoded mixture.
Paper 3 · mAbs
Bispecific antibodies that engage pIgR enrich in mucosa in cynomolgus monkeys
A pIgR-binding bispecific increases lung-lavage exposure in cynomolgus monkeys while shortening serum half-life, connecting mucosal enrichment with systemic loss.
Core finding
Marks et al. recruited the IgA transport receptor pIgR by adding a pIgR-binding VHH to an anti-hemagglutinin IgG. At a matched 5 mg/kg intravenous dose in cynomolgus monkeys, the bispecific produced about 5.5-fold higher bronchoalveolar-lavage exposure while shortening serum half-life from about 9.5 to 1.6 days. The paired measurements establish a redistribution of exposure accompanied by faster systemic disappearance.
What's novel
The study connects receptor-targeted delivery with a tissue-expression analysis that helps interpret its pharmacokinetics. Much higher liver pIgR expression in mice than in primates identifies a specific anatomical difference relevant to the disposition of a pIgR-binding construct.
Limitations
The faster serum decline cannot be apportioned between transcytosis and other disposition pathways, so it should not be treated entirely as productive mucosal delivery. Uncorrected lavage dilution also prevents direct conversion of the relative exposure gain into an epithelial-lining-fluid concentration for an exposure–response analysis.
In context
The work treats an epithelial transport pathway as a means of changing where an IgG acts. Its pharmacological significance rests on the balance between mucosal enrichment and systemic drug loss, making the two compartments necessary parts of the same delivery argument.
Paper 4 · CPT: Pharmacometrics & Systems Pharmacology
Integrating a Tumor Size-Overall Survival Model Into a Spatial Quantitative Systems Pharmacology Framework for Antibody-Drug Conjugates in Non-Small Cell Lung Cancer
A spatial ADC framework connects distribution, tumor response and survival, expressing simulated dose escalation in terms of modeled benefit and payload exposure.
Core finding
Nikfar et al. connected whole-body ADC pharmacokinetics and spatial tumor transport with an empirical tumor-size–survival model for T-DXd and Dato-DXd in NSCLC. Simulated T-DXd dose escalation from 4.4 to 6.4 mg/kg increased response from about 31% to 56% and median survival from 14.0 to 17.8 months, alongside a 45% increase in payload exposure. The framework therefore expresses a dose comparison in terms of both modeled benefit and exposure cost.
What's novel
The integration carries spatially modeled drug action through tumor-size trajectories to a clinical survival endpoint. It also makes the calibration stages distinguishable: two PK parameters are estimated from serum data, while a survival dispersion parameter is adjusted separately.
Limitations
Aggregate PK and tumor-response agreement does not uniquely identify the intratumoral transport and killing mechanisms, so the spatial predictions remain conditional on their assumptions. Survival depends on an empirical tumor-size relationship, and payload AUC represents exposure rather than a quantified adverse-event risk.
In context
The contribution is a connected framework for dose-scenario analysis across distribution, tumor response and survival. Its outputs are most informative when treated as consequences of an explicit model, rather than as independently established measurements of tissue exposure or a complete benefit–risk assessment.
Primary sources
- [1] OAS-nano: the Observed VHH Space Database (Nucleic Acids Research)
- [2] Orthogonal Fc engineering enables multiplexed delivery of mRNA-encoded bispecific antibodies that constrain viral escape (Science Translational Medicine)
- [3] Bispecific antibodies that engage pIgR enrich in mucosa in cynomolgus monkeys (mAbs)
- [4] Integrating a Tumor Size-Overall Survival Model Into a Spatial Quantitative Systems Pharmacology Framework for Antibody-Drug Conjugates in Non-Small Cell Lung Cancer (CPT: Pharmacometrics & Systems Pharmacology)